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Abstract Regulatory T-cells play an important role in
the regulation of the immune response and the media-
tion of dominant immunologic tolerance. We have
previously shown that these cells are elevated in tumors
and blood of patients with glioblastoma multiforme.
Heme oxygenase-1, a rate-limiting enzyme in heme
catabolism, has also been shown to accumulate during
glioma progression and to play a critical role in FoxP3
mediated immune suppression. In this study, we inves-
tigated the correlation between FoxP3 and HO-1
expression in patients with various grades of astrocy-
toma (WHO grade II–IV). Using qualitative and
quantitative reverse transcriptase–polymerase chain
reaction and quantitative flow cytometry analyses, we
analyzed FoxP3 and HO-1 expression in 19 patients
with different grades of astrocytoma. We observed the
highest level of FoxP3 expression in patients with grade
IV tumors (11.54 ± 1.95%) vs. grade III (6.74 ± 0.19%)
or grade II (2.53 ± 0.11%) (P < 0.05). Moreover, in
grade IV tumors, the frequency of HO-1 mRNA
expression in CD4+CD25+ cells was 11.8 ± 2.45% vs.
7.42 ± 0.31% in grade III and 2.33 ± 0.12% in grade II.
Tumor infiltrating Treg stained positively with anti-HO-1
antibody. The expression of HO-1 correlated with
CD4+CD25+FoxP3+ infiltration (r = 0.966). Our results
confirm that HO-1 expressing Treg accumulate during
glioma progression. This study also suggests that HO-1
mRNA expression is linked to the induction of Foxp3
in CD4+CD25+ glioma infiltrating Treg. These findings
support the suppressive role played by regulatory
T-cells in the growth of malignant brain tumors.
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Introduction
Regulatory T-cells (also known as CD4+CD25+FoxP3+,
Treg) are a specialized subpopulation of T-cells that
act to suppress activation of the immune system and
thereby maintain immune system homeostasis and
tolerance to self. There is increasing evidence for the
existence of elevated numbers of regulatory T-cells in
solid tumors and hematological malignancies [1–10].
The presence of infiltrating Treg may be detrimental to
the host defense against the tumor, while the presence
of effector T lymphocytes, including CD8+ and non-
regulatory CD4+ helper T-cells may be beneficial. We
have previously shown that there is an increase in the
number of Treg both in tumor infiltrating lymphocytes
as well as peripheral blood of patients with glioblas-
toma multiforme (GBM) [11]. Moreover, we have also
shown that depletion of Treg prolongs the survival of
mice with experimental brain tumors [12].
Heme oxygenase (HO) is the rate-limiting enzyme
in the catabolism of heme to biliverdin, carbon
monoxide (CO), and free iron. To date, three isoforms
of mammalian HO have been identified: HO-1, HO-2,
and HO-3 [13]. HO-1 is inducible by a variety of
stimuli, in particular, oxidative stress [14, 15]. HO-2
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and HO-3 are constitutive iosozymes, found ubiqui-
tously throughout the body, with high expression in
brain and testes [16, 17]. Induction of HO-1 expression
has been associated with neuroprotection during
hyperthermia in glial cells [18] and during hypoxia [19].
HO-1 expression has also been observed in a wide
range of experimental diseases of the rodent brain such
as traumatic brain injury [20], ischemia [21], and hu-
man Alzheimer’s disease [22]. In brain tumors,
elevated HO-1 expression has been observed [23, 24],
and in at least one report, it would appear that HO-1
accumulates during oligodenodroglioma progression
[25].
The exact functional role of HO-1 expression is not
fully understood in T-cells. However, growing evidence
has shown that human Treg constitutively express HO-
1 and that HO-1 inhibits T-cell proliferation [26].
Over-expression of HO-1 further renders T-cells
resistant to Fas-mediated apoptosis [27]. Most recently,
FoxP3, which encodes a forkhead/winged-helix tran-
scription repressor specifically expressed in Treg, has
been shown to induce HO-1 expression [28]. Taken
together, these studies suggest that HO-1 may be an
important effector of FoxP3-mediated immune sup-
pression and an important target for further clinical
development.
In the present study, we investigated the expression
of HO-1 and Treg infiltration in various grades of hu-
man glioma. Both qualitative and quantitative reverse
transcription polymerase chain reaction was used to
demonstrate HO-1 and FoxP3 gene expression. Flow
cytometry was used to quantify Treg infiltration. We
report here for the first time that HO-1 and FoxP3
expression directly correlates with tumor grade in
patients with malignant glioma.
Materials and methods
Patient samples
Resected specimens from 19 patients who underwent
operations in the Division of Neurosurgery at the
University of Chicago from 2004 to 2006 were evalu-
ated in this study. According to the WHO classifica-
tion, tumors included three grade II astrocytomas, four
grade III astrocytomas, and 12 grade IV astrocytomas
(Table 1). Healthy brain controls (n = 4) consisted of
surgical specimens obtained during temporal lobe
resections for seizure focus. All patients received
perioperative steroids. Histological confirmation of the
diagnosis, for both tumors and normal cortex, was
obtained in all cases. Of note, only normal and healthy
brain rather than diseased tissue, was used for controls.
All surgical specimens were analyzed immediately
after removal. This study was approved by the Insti-
tutional Review Board of the University of Chicago.
Cell sorting
The separation of CD4+CD25– cells from CD4+CD25+
cells from brain tumor samples was done by positive
selection using Treg Isolation Kit (Miltenyi Biotec,
Auburn, CA). Briefly, 1 · 107 cells were resuspended
in 80 ll buffer and the cells were magnetically labeled
by adding 20 ll of anti-CD25 microbeads. The cells
were incubated for 15 min and then washed by cen-
trifugation and resuspeded in 1 ml of buffer per
1.25 · 108 cells. CD4+CD25+ regulatory T-cells were
isolated by positive selection with MS Columns. The
effluent was collected; the purity of cells was analyzed
by flow cytometry and was more than 90%.
Multi-color flow cytometry analysis
One million tumor infiltrating lymphocytes (TIL) were
resuspended in staining buffer (3% FBS in PBS).
Tumor cell suspensions were prepared by homogeni-
zation of the tumor with a cell strainer and washing
of the cells with staining buffer. Erythrocytes were
lysed and cells were then stained with various anti-
bodies. Monoclonal antibodies to CD3, CD4, CD25,
and Foxp3 were obtained from BD Biosciences (San
Jose, CA). The analysis of CD4+CD25+ T-cells was
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performed as a percentage of total CD3+ cells in TILs.
Monoclonal antibody to HO-1 was from Stressgen
Biotechnologies (Victoria, BC). These monoclonal
antibodies were directly coupled to fluorescein isothi-
ocyanate, phycoerythrin, or phycoerythrin-indotri-
carbocyanin. Antibodies were used at 5 lg/ml and
staining was done in fluorescence-activated cell sorting
(FACS) buffer on ice for 45 min. Surface marker
expression on TIL cells was visualized with FAC-
SCaliburTM (BD Biosciences) and was analyzed with
FlowJo software (BD Biosciences). Tumor cells sorting
without tumor infiltrating lymphocyte was done with a
MoFlo cell sorter (Cytomation, Fort Collins, CO).
Semiquantitative RT-PCR and real-time PCR
Total cellular RNA was isolated using RNeasy kit
(Ambion Inc. Austin, TX) according to the manufac-
turer’s protocol. Equivalent amounts of RNA were
reverse-transcribed with the superscript II-RT kit
(Invitrogen). The cDNA amplification was analyzed
quantitatively by incorporation of SYBR Green
(Applied Biosystems) into double stranded DNA. PCR
was done in a total volume of 25 ll containing 1 ll
cDNA template, 0.5 lM of each primer, and SYBR
Green Master Mix (Applied Biosystems, Foster City,
CA) under the following conditions: 15 min hot start at
95C, 15 s denaturation at 95C, 20 s annealing of
primers at 54C, and 15 s elongation at 72C, for 32–35
cycles. Gene expression was analyzed with the ABI
PRISM 7300 Sequence Detection Software version
1.9.1 (Applied Biosystems). Sample results were nor-
malized by dividing the value of the unknown gene by
the value of the endogenous reference gene encoding
glyceraldehyde phosphate dehydrogenase (GAPDH).
Quadruplicate reactions were done with all cDNA
samples. We used the following primers (Invitrogen,
Carlsbad, CA): HO-1 forward (5¢-ACT TTC AGA
AGG GTC AGG TGT CC-3¢); HO-1 reverse (5¢-TTG
AGC AGG AA G GCG GTC TTA G-3¢); Foxp3 for-
ward (5¢-ATG CCT CCT CTT CTT CCT TGA-3¢);
Foxp3 reverse (5¢-ATT GTG CCC TGC CCT TCT
CA-3¢); GAPDH forward (5¢-GGC ATG GAC TGT
GGT CAT GA-3¢), and GAPDH reverse (5¢-TGC
ACC ACC AAC TGC TTA GC-3¢). HO-1 and Foxp3
mRNA levels were normalized to total CD3+ T-cells.
Statistical analysis
Statistical analysis was performed with StatView soft-
ware (SAS). Differences in continuous variables
between groups were tested by ANOVA with the
Scheff ‘ F-test used as a post hoc test. Correlation was
analyzed by multiple linear regression method. The
observed differences were considered statistically
significant if P was less than 0.05. All data are
expressed as mean ± SEM.
Results
CD4+CD25+ T-cell infiltration increases with tumor
grade
The CD4+CD25+ T-cells were gated via the forward
and side scatter properties of TIL (Fig. 1A). Analysis
of TIL from glioma patients shows an increase in
CD4+CD25+ frequency with increasing tumor grade
(Fig. 1B). The percentage of Treg was 11.33 ± 1.52%
(range, 10.46–13.5%) in grade II, 15.75 ± 1.5% (range,
14.88–17.5%) in grade III, and 24.85% ± 2.67%
(range, 20–28.4%) in grade IV. The observed increase
in Treg between grades II and III glioma as well as
grades III and IV was statistically significant
(P < 0.02).
Tumor infiltrating CD4+CD25+ T-cells express
FoxP3
Given that FoxP3 is a marker for Treg cells, we exam-
ined FoxP3 mRNA expression in sorted CD4+CD25+
and CD4+CD25– in different tumor grades. First, FoxP3
mRNA expression was analyzed by semiquantitative
RT-PCR and then quantified by real-time PCR. As
shown in Fig. 2, the expression of FoxP3 mRNA
increased with tumor grade. In fact, we observed the
highest level of FoxP3 expression in patients with grade
IV tumors (11.54 ± 1.95; range [8.12–13.74%]) vs.
grade III (6.74 ± 0.19%; range [6.61–6.88%]) or grade
II (2.53 ± 0.11%; range [2.54–2.61%]) (P < 0.05),
confirming that CD4+CD25+FoxP3+ T-cells preferen-
tially accumulate in high-grade tumors.
Expression of HO-1 depends on the presence
of tumor infiltrating CD4+CD25+FoxP3+ T-cells
To determine whether the reported expression of HO-
1 in brain tumors is a function of tumors cells or the
presence of regulatory T-cells, we examined HO-1
expression in both tumor cells and glioma infiltrating
lymphocytes. The expression of HO-1 was first ana-
lyzed by semi-quantitative RT-PCR. As shown in
Fig. 3A, HO-1 mRNA was detected in all glioma
samples. However, the detection of HO-1 depended
on the presence of tumor infiltrating lymphocytes as
no HO-1 was detected in sorted tumor cells alone.
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Furthermore, real-time PCR demonstrated a signifi-
cant increase in HO-1 mRNA expression (P < 0.05)
depending on the tumor grade. In grade IV tumors,
the frequency of HO-1 mRNA expression in
CD4+CD25+ cells was 11.8 ± 2.45% (range: 8.14–
15.33%) vs. 7.42 ± 0.31% (range: 7.2–7.65%) in grade
III, and 2.33 ± 0.12% (range: 2.25–2.42%) in grade II
(Fig. 3B).
Induction of HO-1 expression in
CD4+CD25+FoxP3+ T-cells is dependent
on tumor grade
To further confirm that HO-1 was expressed only by
glioma infiltrating Treg, we performed a FACS analysis
of total CD4+ T-cells and CD4+CD25+FoxP3+ after
gating in total CD3+ T-cells, using anti-HO-1 mAb.
The frequency of HO-1 expression was analyzed in
various tumor grades. The results, shown in Fig. 4A,
illustrate progressive HO-1 expression in glioma infil-
trating total CD4+ T-cells. The percentage of HO-1
expressing Treg was 31.1 ± 2.2% in grade IV tumors as
compared to 12 ± 1.7% grade III tumors, and
7.78 ± 1.1% grade II tumors (P < 0.02). Furthermore,
the induction of HO-1 expression was highest in
CD4+CD25+FoxP3+ subset purified from patients with
grade IV glioma (92.3 ± 1.75%) as compared to grade
III (70.3 ± 2.3%) or grade II tumors (56.4 ± 2.86%)
(P < 0.02) (Fig. 4B).
The level of HO-1 directly correlates with FoxP3
expression
The expression of HO-1 was correlated with
CD4+CD25+FoxP3+ infiltration. The coefficient of
correlation between HO-1 mRNA and Foxp3 mRNA
Fig. 1 Frequency of tumor
infiltrating lymphocytes (TIL)
in patient with astrocytoma
(grade II–IV). (A) Treg
infiltration in human
astrocytoma was examined by
flow cytometry analysis of
CD4 and CD25 expression of
electronically gated TIL cells.
(B) Figure B shows the
frequency of Treg with grade
of disease. The mean
frequency of regulatory
T-cells was 11.33 ± 1.52%
(range: 10.46–13.5%) in grade
II, 15.75 ± 1.5% (range:
14.88–17.5%) in grade III,
and 24.85 ± 2.67% (range:
20–28.4%) in grade IV glioma
tumors (P < 0.02) in total
CD3+ T-cells
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was 0.966 (Fig. 5). This result confirms that HO-1
mRNA expression correlates with the induction of
Foxp3 in CD4+CD25+ glioma infiltrating Treg.
Discussion
Heme oxygenase-1, a key enzyme in heme catabolism,
has recently been reported to be expressed by human
brain tumors [23], to represent a useful marker for
angiogenesis in human gliomas [24], and to accumulate
during oligodendroglioma progression [25]. To date,
only macrophages/microglia present in the stromal
compartment of tumors have been shown to express
HO-1 [24, 25]. In this study, we provide the first report
to show that the expression of HO-1 and FoxP3 directly
correlate with tumor grade. Moreover, we show that the
expression of HO-1 is not unique to gliomas but is
rather a function of Treg infiltration, and the increased
infiltration of high-grade tumors with Treg is an
important determinant of the immunosuppressive
environment exhibited by malignant brain tumors.
These are significant findings, which elucidate the
mechanism of HO-1 induction and expression in human
gliomas.
HO-1 has an important role in rapid tumor growth
because of its antioxidative and antiapoptotic effects
[29, 30]. Indeed, there is convincing evidence that
accumulation of HO-1 expressing macrophages in
necrotic areas of malignant brain tumors contributes
to neoplastic growth and tissue damage [24]. The
expression of HO-1 is activated in response to vari-
ous environmental insults, including hypoxia, heat
shock, heavy metal toxicity, and UV light irradiation
[31, 32]. Although the accumulation of HO-1
expressing Treg may be induced by irradiation and
chemotherapy administered to the patients (Table 1),
our published findings of Treg infiltration even in
newly diagnosed gliomas [11] would argue against
this hypothesis. Indeed, even in the present study we
did not detect any significant difference in Treg
infiltration between newly diagnosed versus recurrent
Fig. 2 Foxp3 expression in Treg from glioma patients compared
to glioma tumor sorted without TIL or healthy brain controls.
(A) RT-PCR of FoxP3 mRNA purified from isolated
CD4+CD25+, CD4+CD25– T-cells, sorted tumor cells without
TIL, or healthy brain. The reaction was positive in CD4+CD25+
isolated from patients at different stage of disease, but negative
in CD4+CD25– T-cells, sorted tumor cells without TIL, and
healthy brain. (B) Foxp3 quantification in purified CD4+CD25+
in different tumor grades. The level of FoxP3 expressed is grade
IV tumors was higher (11.54 ± 1.95%; range: 8.12–13.74%)
compared to grade III (6.74 ± 0.19%; range: 6.61–6.88%) or
grade II (2.53 ± 0.11%; range: 2.54–2.61%) (P < 0.05). Of note,
there was a total absence of FoxP3 expression in healthy brain
and sorted tumor cells. GAPDH expression was used to
normalize gene expression. Relative expression was calculated
for FoxP3 gene by using DCT method. The data shown is the
mean ± SD
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grade IV astrocytomas. As such, we propose that
Treg progressively infiltrate gliomas at various stages
of the disease. In turn, this leads to localized HO-1
expression. The expression of HO-1 by Treg along
with local tissue hypoxia/re-oxygenation stimulates a
number of cytokines, proteolytic enzymes, and
inhibitors, which play key role in the angiogenesis
cascade. Indeed, HO-1 mediated heme degradation is
the primary mechanism for cellular carbon monoxide
(CO) production, and reactive oxygen intermediates,
including CO, induce angiogenesis in vitro and in
vivo [33]. Most recent studies confirm that HO-1 is a
useful marker for neovascularization of human glio-
mas [24].
The exact role of HO-1 expression is not fully
understood in T-cells. However, growing evidence has
shown that HO-1 and its byproduct, CO, suppress T-cell
proliferation [34, 35]. The over-expression of HO-1
results in the inhibition of several immune effector
functions and thus provides an explanation for stress-
induced immunosuppression [36]. Moreover, human
CD4+CD25+ T-cell constitutively express HO-1 [26]. It
would appear the FoxP3 induces HO-1 expression and
the suppressive effect of Foxp3 is not observed in the
presence of HO-1 siRNA [28]. These findings provide a
compelling argument that human FoxP3 may be a
crucial regulatory gene for the expression of HO-1 and
that HO-1 is engaged in FoxP3 mediated immune
suppression.
In conclusion, we have shown that (1) Treg pro-
gressively infiltrate gliomas with increasing tumor
grade; and (2) the expression of HO-1 directly corre-
lates with the expression of Foxp3, a marker of Treg.
Although we are aware that the small number of
patients with grade II and grade III tumor may limit
these conclusions, the data provides a compelling
argument for a more extensive investigation of HO-1
and FoxP3 expression in a larger number of patients.
Our findings suggest that, at least in part, the
expression of HO-1 by gliomas is dependent on the
presence of CD4+CD25+ regulatory T-cells. Selective
targeting of either HO-1 or FoxP3 may therefore have
important therapeutic implications in the setting of
malignant gliomas.
Fig. 3 HO-1 expression in Treg from glioma patients compared
to glioma tumor sorted without TIL or healthy brain controls.
(A) RT-PCR of HO-1 mRNA prepared from purified
CD4+CD25+, CD4+CD25– T-cells, sorted tumor cells without
TIL, and healthy brain. The reaction was positive in CD4+CD25+
isolated from patients at different stage of disease, but negative
in CD4+CD25– T-cells, sorted tumor cells without TIL, or
healthy brain. (B) HO-1 quantification in isolated CD4+CD25+
in different tumor grades. The level of HO-1 expressed in grade
IV tumors was higher (11.8 ± 2.45%; range: 8.14–15.33%)
compared to grade III (7.42 ± 0.31%; range: 7.2–7.65%) or
grade II (2.33 ± 0.12%; range: 2.25–2.42%) (P < 0.05). Total
absence of HO-1 expression was noted in healthy brain and
sorted tumor cells. GAPDH expression was used to normalize
gene expression. Relative expression was calculated for HO-1
gene by using DCT method. The data shown is the mean ± SD
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